Recursion Pharmaceuticals Inc. (RXRX): Price and Financial Metrics Recent IPO
GET POWR RATINGS... FREE!
RXRX Stock Price Chart Interactive Chart >
RXRX Price/Volume Stats
|Current price||$36.43||52-week high||$37.71|
|Prev. close||$35.04||52-week low||$19.68|
|Day high||$37.71||Avg. volume||480,652|
|50-day MA||$0.00||Dividend yield||N/A|
|200-day MA||$0.00||Market Cap||6.13B|
Recursion Pharmaceuticals Inc. (RXRX) Company Bio
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people’s lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.
RXRX Latest News Stream
|Loading, please wait...|
RXRX Latest Social Stream
View Full RXRX Social Stream
Latest RXRX News From Around the Web
Below are the latest news stories about Recursion Pharmaceuticals Inc that investors may wish to consider to help them evaluate RXRX as an investment opportunity.
Recursion Announces its First Major Multidisciplinary Expansion, in Toronto, to Further Tech-Enabled Drug Discovery
Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering, today announced its intention to soon launch its first major multidisciplinary expansion beyond its Utah headquarters, with plans to hire up to 50 people in Toronto by the end of 2021.
Recursion Announces First Internally-Developed NCE Advanced to IND-Enabling Studies to Potentially Treat Clostridium difficile Colitis
Recursion Pharmaceuticals, Inc. (Nasdaq : RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning (ML), and engineering, today announced the company has initiated investigational new drug (IND)-enabling studies for REC-163964, a first-in-class, small molecule toxin inhibitor for possible prevention of recurrent Clostridium difficile (C. difficile) infections and potential prophylactic use in high-risk patients.
Shares of Recursion Pharmaceuticals (RXRX) have shot up 10.4% in afternoon trading following a disclosure that Cathie Wood's ARK Genomic Revolution ETF (ARKG) added to its position in the biotech.The fund bought 14,440 shares yesterday, with Recursion now accounting for a 0.0039% stake in the fund.Assuming yesterday's closing price, the investment was...
Especially for companies that are expected to be growing right out of the gate, getting in during the market's initial feeding frenzy sometimes means buying a stock when it's as cheap as it will ever be. In this vein, Recursion Pharmaceuticals (NASDAQ: RXRX) and Biomea Fusion (NASDAQ: BMEA) are a pair of biotechs that had their IPOs last week, and both have unique value for investors that could make them worth a (speculative) buy. Recursion's information technology-heavy approach to drug discovery could make it a rising star on the basis of its already extensive list of development collaborations alone.
RXRX Price Returns